{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:02:04Z","timestamp":1763755324231,"version":"3.45.0"},"reference-count":94,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology Nursing Forum"],"published-print":{"date-parts":[[2005,5,1]]},"DOI":"10.1188\/05.onf.589-603","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T10:35:38Z","timestamp":1139913338000},"page":"589-603","source":"Crossref","is-referenced-by-count":21,"title":["Cancer Treatment-Induced Bone Loss in Patients With Breast or Prostate Cancer"],"prefix":"10.1188","volume":"32","author":[{"given":"Cathy","family":"Maxwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Hallquist Viale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,8]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Basaria, S., Lieb, J., II, Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., et al. (2002). Long-term effects of androgen deprivation therapy in prostate cancer patients. <i>Clinical Endocrinology, 56<\/i>, 779-786.","DOI":"10.1046\/j.1365-2265.2002.01551.x"},{"key":"E00002","unstructured":"Baum, M., Buzdar, A.U., Cuzick, J., Forbes, J., Houghton, J.H., Klijn, J.G., et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. <i>Lancet, 359<\/i>, 2131-2139."},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Begerow, B., Pfeifer, M., Pospeschill, M., Scholz, M., Schlotthauer, T., Lazarescu, A., et al. (1999). Time since vertebral fracture: An important variable concerning quality of life in patients with postmenopausal osteoporosis. <i>Osteoporosis International, 10<\/i>, 26-33.","DOI":"10.1007\/s001980050190"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Berruti, A., Dogliotti, L., Terrone, C., Cerutti, S., Isaia, G., Tarabuzzi, R., et al. (2002). Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. <i>Journal of Urology, 167<\/i>, 2361-2367.","DOI":"10.1016\/S0022-5347(05)64985-3"},{"key":"E00005","doi-asserted-by":"crossref","unstructured":"Berruti, A., Tucci, M., Terrone, C., Gorzegno, G., Scarpa, R.M., Angeli, A., et al. (2002). Background to and management of treatment-related bone loss in prostate cancer. <i>Drugs and Aging, 19<\/i>, 899-910.","DOI":"10.2165\/00002512-200219120-00002"},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Bines, J., Oleske, D.M., & Cobleigh, M.A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. <i>Journal of Clinical Oncology, 14<\/i>, 1718-1729.","DOI":"10.1200\/JCO.1996.14.5.1718"},{"key":"E00007","unstructured":"Brown, J.P., & Josse, R.G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. <i>Canadian Medical Association Journal, 167<\/i>(10, Suppl.), S1-S34."},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Bruning, P.F., Pit, M.J., de Jong-Bakker, M., van den Ende, A., Hart, A., & van Enk, A. (1990). Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. <i>British Journal of Cancer, 61<\/i>, 308-310.","DOI":"10.1038\/bjc.1990.58"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N., & Eisman, J.A. (1999). Mortality after all major types of osteoporotic fracture in men and women: An observational study. <i>Lancet, 353<\/i>, 878-882.","DOI":"10.1016\/S0140-6736(98)09075-8"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Chen, Z., Maricic, M., Nguyen, P., Ahmann, F.R., Bruhn, R., & Dalkin, B.L. (2002). Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. <i>Cancer, 95<\/i>, 2136-2144.","DOI":"10.1002\/cncr.10967"},{"key":"E00011","unstructured":"ClinicalTrials.gov. (2004a). Calcium with or without estrogen and\/or risedronate in preventing osteoporosis in patients with prostate cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00043069?order=1'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00043069?order=1<\/a>"},{"key":"E00012","unstructured":"ClinicalTrials.gov. (2004b). Risedronate in preventing bone loss in premenopausal women receiving chemotherapy for primary breast cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00054418?order=2'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00054418?order=2<\/a>"},{"key":"E00013","unstructured":"ClinicalTrials.gov. (2004c). Tamoxifen to prevent bone loss and heart disease in premenopausal women receiving chemotherapy for stage I or stage II breast cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00005605?order=1'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00005605?order=1<\/a>"},{"key":"E00014","unstructured":"ClinicalTrials.gov. (2004d). Zoledronate and estradiol in preventing bone loss in patients with prostate cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00049491?order=1'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00049491?order=1<\/a>"},{"key":"E00015","unstructured":"ClinicalTrials.gov. (2004e). Zoledronate, calcium, and vitamin D in preventing bone loss in women receiving adjuvant chemotherapy for breast cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00022087?order=1'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00022087?order=1<\/a>"},{"key":"E00016","unstructured":"ClinicalTrials.gov. (2004f). Zoledronate in preventing bone loss in premenopausal women receiving chemotherapy after surgery for early stage breast cancer. Retrieved February 23, 2004, from <a target=\"_blank\" href='http:\/\/clinicaltrials.gov\/ct\/show\/NCT00049452?order=9'>http:\/\/clinicaltrials.gov\/ct\/show\/NCT00049452?order=9<\/a>"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <i>New England Journal of Medicine, 350<\/i>, 1081-1092.","DOI":"10.1056\/NEJMoa040331"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Cooper, C. (1997). The crippling consequences of fractures and their impact on quality of life. <i>American Journal of Medicine, 103<\/i>(2A), 12S-17S.","DOI":"10.1016\/S0002-9343(97)90022-X"},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Cummings, S.R., Bates, D., & Black, D.M. (2002). Clinical use of bone densitometry: Scientific review. <i>JAMA, 288<\/i>, 1889-1897.","DOI":"10.1001\/jama.288.15.1889"},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Cummings, S.R., & Melton, L.J., III. (2002). Epidemiology and outcomes of osteoporotic fractures. <i>Lancet, 359<\/i>, 1761-1767.","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Daniell, H.W. (1997). Osteoporosis after orchiectomy for prostate cancer. <i>Journal of Urology, 157<\/i>, 439-444.","DOI":"10.1016\/S0022-5347(01)65165-6"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Daniell, H.W., Dunn, S.R., Ferguson, D.W., Lomas, G., Niazi, Z., & Stratte, P.T. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. <i>Journal of Urology, 163<\/i>, 181-186.","DOI":"10.1016\/S0022-5347(05)68000-7"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Dawson-Hughes, B., Harris, S.S., Krall, E.A., & Dallal, G.E. (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. <i>New England Journal of Medicine, 337<\/i>, 670-676.","DOI":"10.1056\/NEJM199709043371003"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Delmas, P.D. (2002). Treatment of postmenopausal osteoporosis. <i>Lancet, 359<\/i>, 2018-2026.","DOI":"10.1016\/S0140-6736(02)08827-X"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Delmas, P.D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997). Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. <i>Journal of Clinical Oncology, 15<\/i>, 955-962.","DOI":"10.1200\/JCO.1997.15.3.955"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Delmas, P.D., Eastell, R., Garnero, P., Seibel, M.J., & Stepan, J. (2000). The use of biochemical markers for bone turnover in osteoporosis. <i>Osteoporosis International, 11<\/i>(Suppl. 6), S2-S17.","DOI":"10.1007\/s001980070002"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998). The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to intermittent cyclic etidronate therapy. <i>Cancer, 83<\/i>, 1561-1566.","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z"},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Diamond, T.H., Higano, C.S., Smith, M.R., Guise, T.A., & Singer, F.R. (2004). Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. <i>Cancer, 100<\/i>, 892-899.","DOI":"10.1002\/cncr.20056"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Diamond, T.H., Winters, J., Smith, A., De Souza, P., Kersley, J.H., Lynch, W.J, et al. (2001). The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combine androgen blockade: A double blind, randomized, placebo-controlled crossover study. <i>Cancer, 92<\/i>, 1444-1450.","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M"},{"key":"E00030","unstructured":"Eastell, R., Hannon, R.A., Cuzick, J., Clack, G., & Adams, J.E. (2002). <i>Effect of anastrozole on bone density and bone turnover: Results of 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) study.<\/i> Abstract 1170 presented at the 24th annual meeting of the American Society of Bone and Mineral Research, San Antonio, TX."},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Eriksson, S., Eriksson, A., Stege, R., & Carlstrom, K. (1995). Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. <i>Calcified Tissue International, 57<\/i>, 97-99.","DOI":"10.1007\/BF00298427"},{"key":"E00032","unstructured":"Finkelstein, J.S. (2000). Osteoporosis. In L. Goldman & J.C. Bennett (Eds.), <i>Cecil textbook of medicine<\/i> (21st ed., pp. 1366-1373). Philadelphia: Saunders."},{"key":"E00033","unstructured":"Follin, S.L. (2003). Update in osteoporosis. In B.A. Mueller, K.E. Bertch, T.S. Dunsworth, S.C. Fagan, M.S. Hayney, M.B. O'Connell, et al. (Eds.), <i>Pharmacotherapy self-assessment program: Book 11 women's health, men's health<\/i> (4th ed., pp. 329-366). Kansas City, MO: American College of Clinical Pharmacy."},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Gholz, R.C., Conde, F., & Rutledge, D.N. (2002). Osteoporosis in men treated with androgen suppression therapy for prostate cancer. <i>Clinical Journal of Oncology Nursing, 6<\/i>, 88-93.","DOI":"10.1188\/02.CJON.88-93"},{"key":"E00035","unstructured":"Gnant, M., Hausmaninger, H., Samonigg, H., Mlineritsch, B., Taucher, S., Luschin-Ebengreuth, G., et al. (2002). Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (\u00b1 zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. <i>Breast Cancer Research and Treatment, 76<\/i>(Suppl.), 531."},{"key":"E00036","unstructured":"Goss, P.E. (2004). <i>NCIC CTG MA.17: Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer.<\/i> Presentation at the 40th annual meeting of the American Society of Clinical Oncology, New Orleans, LA."},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Piccart, M.J., et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. <i>New England Journal of Medicine, 349<\/i>, 1793-1802.","DOI":"10.1056\/NEJMoa032312"},{"key":"E00038","doi-asserted-by":"crossref","unstructured":"Graham, D.Y., & Malaty, H.M. (2001). Alendronate and naproxen are synergistic for development of gastric ulcers. <i>Archives of Internal Medicine, 161<\/i>, 107-110.","DOI":"10.1001\/archinte.161.1.107"},{"key":"E00039","doi-asserted-by":"crossref","unstructured":"Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S., & Tashiro, K. (2000). Incidence of bone fracture in patients receiving luteinizing hormone-releasing agonists for prostate cancer. <i>British Journal of Urology International, 86<\/i>, 449-452.","DOI":"10.1046\/j.1464-410X.2000.00774.x"},{"key":"E00040","doi-asserted-by":"crossref","unstructured":"Higano, C.S. (2003). Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. <i>Urologic Oncology, 21<\/i>, 392-398.","DOI":"10.1016\/S1078-1439(03)00143-1"},{"key":"E00041","doi-asserted-by":"crossref","unstructured":"Higano, C.S. (2004). Understanding treatments for bone loss and bone metastases in patients with prostate cancer: A practical review and guide for the clinician. <i>Urologic Clinics of North America, 31<\/i>, 331-352.","DOI":"10.1016\/j.ucl.2004.01.001"},{"key":"E00042","unstructured":"Higano, C.S., Jiang, P.Y.Z., Miller, M., Pitzel, M., & Jensen, M. (2003). Prospective evaluation of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen therapy. <i>Oncology, 17<\/i>(4, Suppl.), 32-33."},{"key":"E00043","doi-asserted-by":"crossref","unstructured":"Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J., Yee, G.C., Janjan, N.A., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. <i>Journal of Clinical Oncology, 21<\/i>, 4042-4057.","DOI":"10.1200\/JCO.2003.08.017"},{"key":"E00044","doi-asserted-by":"crossref","unstructured":"Hofbauer, L.C., & Khosla, S. (1999). Androgen effects on bone metabolism: Recent progress and controversies. <i>European Journal of Endocrinology, 140<\/i>, 271-286.","DOI":"10.1530\/eje.0.1400271"},{"key":"E00045","doi-asserted-by":"crossref","unstructured":"Jonat, W., Kaufmann, M., Sauerbrei, W., Blamey, R., Cuzick, J., Namer, M., et al. (2002). Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. <i>Journal of Clinical Oncology, 20<\/i>, 4628-4635.","DOI":"10.1200\/JCO.2002.05.042"},{"key":"E00046","doi-asserted-by":"crossref","unstructured":"Jordan, V.C., Gapstur, S., & Morrow, M. (2001). Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. <i>Journal of the National Cancer Institute, 93<\/i>, 1449-1457.","DOI":"10.1093\/jnci\/93.19.1449"},{"key":"E00047","doi-asserted-by":"crossref","unstructured":"Kanis, J.A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. <i>Lancet, 359<\/i>, 1929-1936.","DOI":"10.1016\/S0140-6736(02)08761-5"},{"key":"E00048","doi-asserted-by":"crossref","unstructured":"Kaufman, J.M., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., et al. (2000). Background for studies on the treatment of male osteoporosis: State of the art. <i>Annals of the Rheumatic Diseases, 59<\/i>, 765-772.","DOI":"10.1136\/ard.59.10.765"},{"key":"E00049","unstructured":"Kiralti, B.J., Srinivas, S., Perkash, I., & Terris, M.K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. <i>Urology, 57<\/i>, 127-132."},{"key":"E00050","doi-asserted-by":"crossref","unstructured":"Leder, B.Z., LeBlanc, K.M., Schoenfeld, D.A., Eastell, R., & Finkelstein, J.S. (2003). Differential effects of androgens and estrogens on bone turnover in normal men. <i>Journal of Clinical Endocrinology and Metabolism, 88<\/i>, 204-210.","DOI":"10.1210\/jc.2002-021036"},{"key":"E00051","doi-asserted-by":"crossref","unstructured":"Lips, P., Wilco, C., Graafmans, W.C., Ooms, M.E., Bezemer, D., & Bouter, L.M. (1996). Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. <i>Annals of Internal Medicine, 124<\/i>, 400-406.","DOI":"10.7326\/0003-4819-124-4-199602150-00003"},{"key":"E00052","doi-asserted-by":"crossref","unstructured":"Love, R.R., Mazess, R.B., Barden, H.S., Epstein, S., Newcomb, P.A., Jordan, V.C., et al. (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. <i>New England Journal of Medicine, 326<\/i>, 852-856.","DOI":"10.1056\/NEJM199203263261302"},{"key":"E00053","doi-asserted-by":"crossref","unstructured":"Maillefert, J.F., Sibilia, J., Michel, F., Saussine, C., Javier, R.M., & Tavernier, C. (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. <i>Journal of Urology, 161<\/i>, 1219-1222.","DOI":"10.1016\/S0022-5347(01)61639-2"},{"key":"E00054","doi-asserted-by":"crossref","unstructured":"Melton, L.J., III, Alothman, K.I., Khosla, S., Achenbach, S.J., Oberg, A.L., & Zincke, H. (2003). Fracture risk following bilateral orchiectomy. <i>Journal of Urology, 169<\/i>, 1747-1750.","DOI":"10.1097\/01.ju.0000059281.67667.97"},{"key":"E00055","unstructured":"Messinger-Rapport, B.J., & Thacker, H.L. (2002). Prevention for the older woman: A practical guide to prevention and treatment of osteoporosis. <i>Geriatrics, 57<\/i>(4), 16-18, 21-24, 27."},{"key":"E00056","unstructured":"Miller, P., & Lane, N.E. (2001). Osteoporosis: Clinical and laboratory features. In J.H. Klippel, L.J. Crofford, J.H. Stone, & C.M. Weyand (Eds.), <i>Primer on the rheumatic diseases<\/i> (12th ed., pp. 518-523). Atlanta, GA: Arthritis Foundation."},{"key":"E00057","doi-asserted-by":"crossref","unstructured":"Mincey, B.A., Moraghan, T.J., & Perez, E.A. (2000). Prevention and treatment of osteoporosis in women with breast cancer. <i>Mayo Clinic Proceedings, 75<\/i>, 821-829.","DOI":"10.4065\/75.8.821"},{"key":"E00058","doi-asserted-by":"crossref","unstructured":"Mittan, D., Lee, S., Miller, E., Perez, R.C., Basler, J.W., & Bruder, J.M. (2002). Bone loss following hypogonadism in men with prostate cancer treated with gonadotropin-releasing hormone analogs. <i>Journal of Clinical Endocrinology and Metabolism, 87<\/i>, 3656-3661.","DOI":"10.1210\/jcem.87.8.8782"},{"key":"E00059","doi-asserted-by":"crossref","unstructured":"Morabito, N., Gaudio, A., Lasco, A., Vergara, C., Tallarida, F., Crisafulli, G., et al. (2003). Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. <i>Osteoporosis International, 14<\/i>, 500-506.","DOI":"10.1007\/s00198-003-1397-0"},{"key":"E00060","unstructured":"National Osteoporosis Foundation. (2003). <i>Physician's guide to prevention and treatment of osteoporosis.<\/i> Washington, DC: Author."},{"key":"E00061","unstructured":"National Osteoporosis Foundation. (2004a). America's bone health: The state of osteoporosis and low bone mass. Retrieved January 22, 2004, from <a target=\"_blank\" href='http:\/\/www.nof.org\/advocacy\/prevalence\/index.htm'>http:\/\/www.nof.org\/advocacy\/prevalence\/index.htm<\/a>"},{"key":"E00062","unstructured":"National Osteoporosis Foundation. (2004b). Osteoporosis: Men. Retrieved January 14, 2004, from <a target=\"_blank\" href='http:\/\/www.nof.org\/men\/index.htm'>http:\/\/www.nof.org\/men\/index.htm<\/a>"},{"key":"E00063","unstructured":"Novartis Pharmaceuticals. (2003). Aredia\u00ae [Package insert]. East Hanover, NJ: Author."},{"key":"E00064","unstructured":"Novartis Pharmaceuticals. (2004). Zometa\u00ae [Package insert]. East Hanover, NJ: Author."},{"key":"E00065","unstructured":"O'Connell, M.B. (1999). Osteoporosis and osteomalacia. In J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, & L.M. Posey (Eds.), <i>Pharmacotherapy: A pathophysiological approach<\/i> (4th ed., pp. 1406-1426). Stamford, CT: Appleton and Lange."},{"key":"E00066","doi-asserted-by":"crossref","unstructured":"Oefelein, M.G., Ricchuiti, V., Conrad, W., Seftel, A., Bodner, D., Goldman, H., et al. (2001). Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. <i>Journal of Urology, 166<\/i>, 1724-1728.","DOI":"10.1097\/00005392-200111000-00024"},{"key":"E00067","doi-asserted-by":"crossref","unstructured":"Oursler, M.J., Landers, J.P., Riggs, B.L., & Spelsberg, T.C. (1993). Oestrogen effects on osteoblasts and osteoclasts. <i>Annals of Medicine, 25<\/i>, 361-371.","DOI":"10.3109\/07853899309147298"},{"key":"E00068","unstructured":"Peacock, M., Liu, G., Carey, M., McClintock, R., Ambrosius, W., Hui, S., et al. (2000). Effect of calcium or 25OH vitamin D<sub>3<\/sub> dietary supplementation on bone loss at the hip in men and women over the age of 60. <i>Journal of Clinical Endocrinology and Metabolism, 85<\/i>, 3011-3019."},{"key":"E00069","doi-asserted-by":"crossref","unstructured":"Pfeilschifter, J., & Diel, I.J. (2000). Osteoporosis due to cancer treatment: Pathogenesis and management. <i>Journal of Clinical Oncology, 18<\/i>, 1570-1593.","DOI":"10.1200\/JCO.2000.18.7.1570"},{"key":"E00070","doi-asserted-by":"crossref","unstructured":"Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A., & Ashley, S. (1996). Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. <i>Journal of Clinical Oncology, 14<\/i>, 78-84.","DOI":"10.1200\/JCO.1996.14.1.78"},{"key":"E00071","unstructured":"Procter & Gamble Pharmaceuticals. (2003). Didronel\u00ae [Package insert]. North Norwich, NY: Author."},{"key":"E00072","doi-asserted-by":"crossref","unstructured":"Ramaswamy, B., & Shapiro, C.L. (2003). Osteopenia and osteoporosis in women with breast cancer. <i>Seminars in Oncology, 6<\/i>, 763-775.","DOI":"10.1053\/j.seminoncol.2003.08.028"},{"key":"E00073","doi-asserted-by":"crossref","unstructured":"Recker, R.R., Hinders, S., Davies, K.M., Heaney, R.P., Stegman, M.R., Lappe, J.M., et al. (1996). Correcting calcium nutritional deficiency prevents spine fractures in elderly women. <i>Journal of Bone and Mineral Research, 11<\/i>, 1961-1966.","DOI":"10.1002\/jbmr.5650111218"},{"key":"E00074","doi-asserted-by":"crossref","unstructured":"Reid, I.R., Ames, R.W., Evans, M.C., Gamble, G.D., & Sharpe, S.J. (1995). Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. <i>American Journal of Medicine, 98<\/i>, 331-335.","DOI":"10.1016\/S0002-9343(99)80310-6"},{"key":"E00075","doi-asserted-by":"crossref","unstructured":"Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., et al. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine, 346<\/i>, 653-661.","DOI":"10.1056\/NEJMoa011807"},{"key":"E00076","doi-asserted-by":"crossref","unstructured":"Saarto, R., Blomqvist, C., Valimake, M., Makela, P., Sarna, S., & Elomaa, I. (1997). Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. <i>Journal of Clinical Oncology, 15<\/i>, 1341-1347.","DOI":"10.1200\/JCO.1997.15.4.1341"},{"key":"E00077","doi-asserted-by":"crossref","unstructured":"Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C., Parliament, M.B., Scott, C.G., et al. (2003). Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology, 21<\/i>, 1653-1659.","DOI":"10.1200\/JCO.2003.09.534"},{"key":"E00078","doi-asserted-by":"crossref","unstructured":"Shapiro, C.L., Manola, J., & Leboff, M. (2001). Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. <i>Journal of Clinical Oncology, 19<\/i>, 3306-3311.","DOI":"10.1200\/JCO.2001.19.14.3306"},{"key":"E00079","doi-asserted-by":"crossref","unstructured":"Smith, M.R. (2002). Osteoporosis during androgen deprivation therapy for prostate cancer. <i>Urology, 60<\/i>(Suppl. 3A), 79-86.","DOI":"10.1016\/S0090-4295(02)01579-0"},{"key":"E00080","doi-asserted-by":"crossref","unstructured":"Smith, M.R. (2003a). Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. <i>Drugs and Aging, 20<\/i>, 175-183.","DOI":"10.2165\/00002512-200320030-00002"},{"key":"E00081","doi-asserted-by":"crossref","unstructured":"Smith, M.R. (2003b). Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. <i>Cancer, 97<\/i>(3, Suppl.), 789-795.","DOI":"10.1002\/cncr.11149"},{"key":"E00082","doi-asserted-by":"crossref","unstructured":"Smith, M.R., Eastham, J., Gleason, D.M., Shasha, D., Tchekmedyian, S., & Zinner, N. (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. <i>Journal of Urology, 169<\/i>, 2008-2012.","DOI":"10.1097\/01.ju.0000063820.94994.95"},{"key":"E00083","doi-asserted-by":"crossref","unstructured":"Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., et al. (2001). Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. <i>New England Journal of Medicine, 345<\/i>, 948-955.","DOI":"10.1056\/NEJMoa010845"},{"key":"E00084","doi-asserted-by":"crossref","unstructured":"Taxel, P., Fall, P.M., Albertsen, P.C., Dowsett, R.D., Trahiotis, M., Zimmerman, J., et al. (2002). The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism, 87<\/i>, 4907-4913.","DOI":"10.1210\/jc.2002-020539"},{"key":"E00085","doi-asserted-by":"crossref","unstructured":"Thiebaud, D., Burckhardt, P., Melchior, J., Eckert, P., Jacquet, A.F., Schnyder, P., et al. (1994). Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. <i>Osteoporosis International, 4<\/i>, 76-83.","DOI":"10.1007\/BF01623227"},{"key":"E00086","doi-asserted-by":"crossref","unstructured":"Townsend, M.F., Sanders, W.H., Northway, R.O., & Graham, S.D., Jr. (1997). Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. <i>Cancer, 79<\/i>, 545-550.","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3"},{"key":"E00087","doi-asserted-by":"crossref","unstructured":"Twiss, J.J., Waltman, N., Ott, C.D., Gross, G.J., Lindsey, A.M., & Moore, T.E. (2001). Bone mineral density in postmenopausal breast cancer survivors. <i>Journal of the American Academy of Nurse Practitioners, 13<\/i>, 276-284.","DOI":"10.1111\/j.1745-7599.2001.tb00035.x"},{"key":"E00088","unstructured":"USP DI\u00ae Editorial Group. (Ed). (2004). <i>USP DI\u00ae drug information for the health care professional<\/i> [Electronic version] (24th ed.). Taunton, MA:Micromedex,Inc.RetrievedJuly20,2004,fromhttp:\/\/online.statref.com\/document.aspx?DocID=1&StartDoc=1&EndDoc=4569&FxID=6&offset=7&level=0&State=False&Local=True&SessionID=25E5E6ESFYXRXNKH&"},{"key":"E00089","unstructured":"Vehmanen, L., Saarto, T., Elomaa, P., Makela, P., Valimaki, M., & Blomquist, C. (2001). Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. <i>European Journal of Cancer, 37<\/i>, 2373-2378."},{"key":"E00090","doi-asserted-by":"crossref","unstructured":"Viale, P.H., & Sanchez Yamamoto, D. (2003). Bisphosphonates: Expanded roles in the treatment of patients with cancer. <i>Clinical Journal of Oncology Nursing, 7<\/i>, 393-401.","DOI":"10.1188\/03.CJON.393-401"},{"key":"E00091","doi-asserted-by":"crossref","unstructured":"Vieth, R. (2001). Vitamin D nutrition and its potential health benefits for bone, cancer and other conditions. <i>Journal of Nutritional and Environmental Medicine, 11<\/i>, 275-291.","DOI":"10.1080\/13590840120103120"},{"key":"E00092","doi-asserted-by":"crossref","unstructured":"Vincent, K.R., & Braith, R.W. (2002). Resistance exercise and bone turnover in elderly men and women. <i>Medicine and Science in Sports and Exercise, 34<\/i>, 17-23.","DOI":"10.1097\/00005768-200201000-00004"},{"key":"E00093","doi-asserted-by":"crossref","unstructured":"Ward, R.L., Morgan, G., Dalley, D., & Kelly, P.J. (1993). Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. <i>Bone and Mineral, 22<\/i>, 87-94.","DOI":"10.1016\/S0169-6009(08)80220-6"},{"key":"E00094","unstructured":"WPS Medicare Administrators. (2004). Wisconsin medical policy index: Bisphosphonate drug therapy. Retrieved July 20, 2004, from <a target=\"_blank\" href='http:\/\/www.wpsic.com\/medicare\/policies\/wisconsin\/inj25.shtml'>http:\/\/www.wpsic.com\/medicare\/policies\/wisconsin\/inj25.shtml<\/a>"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/N171V3Q561765870.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:21Z","timestamp":1763754741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/32\/3\/cancer-treatment-induced-bone-loss-patients-breast-or-prostate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5,1]]}},"alternative-id":["N171V3Q561765870"],"URL":"https:\/\/doi.org\/10.1188\/05.onf.589-603","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"type":"print","value":"0190-535X"},{"type":"electronic","value":"1538-0688"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}